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Commentary Lam et al. described two patients diagnosed with Alzheimer's disease (AD), one of whom had discrete prolonged confusional spells and both of whom had interictal temporal lobe spikes on scalp electroencephalography (EEG). Further, upon foramen ovale electrode placement, each had multiple subclinical mesiobasal temporal lobe seizures during sleep. Both patients were subsequently started on levetiracetam. One patient did well, with no seizures and only a mild decline in cognitive functioning 1 year after the procedure. The other patient did not tolerate levetiracetam due to worsened mood; details regarding subsequent medication trials were not provided. The authors discussed the possibility that subclinical spikes and seizures in these patients contribute to the cognitive decline in AD.
There has long been a pathological association between AD and epilepsy, and the connection is tau accumulation. This common pathology is associated with accelerated cognitive decline in both entities. Our understanding of brain tau adversity in clinical epilepsy has recently become more refined, with Tai et al. (1) reporting a "dose" effect. In the resected temporal lobes of 33 persons with epilepsy ages 50-66, the extent of the hyperphosphorylated tau (the pathologic version of tau) correlated with decrements in verbal learning, recall, and naming evaluated longitudinally; these deficits progressed postresection. More evidence supporting the impact of tau in epilepsy is the groundbreaking report by Gheyara et al. (2) , wherein genetic deletion of the Tau 1 allele in mice with Nav 1.1 truncation mutation (R1407X), the mutation present in human Dravet Syndrome, resulted in the mitigation of seizure occurrence, cognitive and behavioral abnormalities, and premature death (2) . These findings suggest not only an association but a causal effect of tau accumulation since changing the cause changed the effect (in mice with R1407X mutation) as well as a dose correlation. However, even in AD, it is not unequivocally accepted that hyperphosphorylated tau accumulation is causative for neurodegeneration and the clinical disease expression (3) .
Another factor associating AD with epilepsy is the genetic influence of the APOE Ɛ4 allele. The APOE gene contributes to the synthesis of apolipoprotein E, which carries cholesterol in the brain in the service of neuronal repair and maintenance, specifically to clear deposits including amyloid accumulation from parenchyma. The presence of APOE Ɛ4 allele imparts a deficiency in this process compared to alleles 1-3, with homozygosity being more harmful than heterozygosity. APOE Ɛ4 allele is associated with an increased incidence of late-onset AD (4). Based on these findings, it can be hypothesized that APOE Ɛ4 would also have an adverse effect in epilepsy, another disease in which neuronal recovery and repair is critically important. Indeed, the presence of the APOE Ɛ4 allele has been reported to impart a risk of earlier age of onset of temporal lobe epilepsy (5), more frequent bilaterality of hippocampal sclerosis (6) and, after accounting for multiple factors including disease duration, impaired verbal learning (7), among other reports of an adverse cognitive association (8, 9) . It has been stated that "APOE is likely the only candidate gene whose association with cognition withstands genome-wide correction and meets the current standards for establishing scientific credibility" (10) .
APOE Ɛ4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy and, to a lesser extent, all the APOE alleles contribute to tauopathy (11) . However, when examining the relationship between APOE Ɛ4 allele and We directly assessed mesial temporal activity using intracranial foramen ovale electrodes in two patients with Alzheimer's disease (AD) without a history or EEG evidence of seizures. We detected clinically silent hippocampal seizures and epileptiform spikes during sleep, a period when these abnormalities were most likely to interfere with memory consolidation. The findings in these index cases support a model in which early development of occult hippocampal hyperexcitability may contribute to the pathogenesis of AD.
Epilepsy and Alzheimer's Disease: Ubiquitous Entities Subject to the Same Cosmic Forces but on Different Astral Planes
epilepsy by causality, a specific association with posttraumatic epilepsy is present (12) . Further, the contribution of tau accumulation itself on cognition in epilepsy is brought into question by the results of a study in which Braak staging for Alzheimer's disease pathology using tau protein immunohistochemistry was carried out in a postmortem series of 138 patients with long-term and mainly drug-resistant epilepsy (12) . The remarkable results are restated here: After controlling for age, the investigators found no clear relationship between seizure frequency, age of onset, and duration of epilepsy with Braak stage. Higher Braak stages were noted with focal more than with generalized epilepsy syndromes (p < 0.01). Pathological evidence of traumatic brain injury that was significantly associated with higher Braak stages (p < 0.001) was present in 30% of patients. Astrocytic-tau protein correlated with the presence of both traumatic brain injury (p < 0.01) and high Braak stage (p < 0.001). Asymmetrical patterns of tau protein accumulation within the sclerotic hippocampus were noted, but hippocampal sclerosis identified in 40% (bilateral in 48%) was not associated with higher Braak stages. In the majority of patients with cognitive decline, the Braak stage was low, indicating causes other than AD pathology. The authors concluded that while there was evidence of accelerated brain aging in severe chronic epilepsy, traumatic brain injury (but not seizures) was associated with tau protein accumulation, and AD pathology was not the sole explanation for cognitive decline associated with epilepsy (13) .
Therefore, the question is whether the tauopathy in temporal lobe epilepsy is simply posttraumatic; traumatic brain injury but not temporal lobe epilepsy is a well-recognized stimulator of pathogenic tau formation (as is mTor hyperactivity, which also has implications for epilepsy; 14). This issue was addressed by Tai et al. (1) , who stated that based on their findings in temporal lobe surgical specimens, the tauopathy of epilepsy is a mixture of tau pathology patterns characteristic of AD and chronic traumatic encephalopathy. They described subpial tau deposition with sparing of the hippocampus but colocalization with mossy fiber sprouting, as well as accelerated cognitive decline associated with the extent of tau pathology. In their series of 33 patients, Tai et al. did not find an association with head injury. It is plausible that temporal lobe epilepsy needs to be added to the list of tauopathies.
Clearly, much clinical and pathological overlap is present between epilepsy and AD. Brain pathology and genetic influences are important for both expression and clinical course of both entities while, fundamentally, the underlying cause for each is unknown. Perhaps due to an enhancement of the tauopathy and the APOE influence, AD patients frequently have seizures. Not surprisingly, epilepsy has an adverse effect on the course and insidiousness of the illness. From a database of patients with cognitive decline at the University of California, San Francisco, Vossel et al. (15) reported that AD patients with epilepsy presented with symptoms of cognitive decline 6.8 years earlier than did AD patients without epilepsy (64.8 vs 70.3 years; p = .001); findings were nearly identical for patients with amnestic mild cognitive impairment. The presence of interictal epileptiform abnormalities was associated with more rapid cognitive decline in this group. In a subsequent report by Vossel et al. (16) , interictal epileptiform activity was detected in 42.4% of 33 AD patients without a history of seizures; these patients had a markedly more rapid cognitive decline than did AD patients without these findings over the 3-year follow-up.
Finally, we need to address the issue of antiseizure treatment for the AD population. As stated by eloquently by Smith, "Epileptiform activity is specific, but not sensitive, for diagnosis of epilepsy as the cause of a transient loss of consciousness or other paroxysmal event that is clinically likely to be epilepsy. EEG has relatively low sensitivity in epilepsy, ranging between 25 to 56 percent. Specificity is better but again variable at 78 to 98 percent" (17) . Therefore, an abnormal interictal epileptiform EEG in AD patients, as with all patients, merits careful consideration regarding treatment for epilepsy, with the incorporation of clinical history into decision making. Certainly, the findings by Lam et al. indicate that, while short of implanting foramen ovale electrodes, abnormal brain physiology with seizures is common in AD patients. Their remarkable discovery suggests that an aggressive and liberal approach towards treating interictal discharges or suspected epileptic events in the AD population is appropriate to maximize cognitive potential and quality of life.
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